Dermatology

Hulio shows comparable efficacy and safety to Humira in treating chronic plaque psoriasis, supporting its FDA interchangeability status.

The FDA approves dupilumab as the first targeted treatment for bullous pemphigoid, offering hope for patients with this debilitating skin condition.

Discover essential tips for sunburn prevention and treatment, insect bite protection, and effective remedies for outdoor fun with family.

Nemolizumab shows promising long-term efficacy in reducing itch and skin lesions for atopic dermatitis, enhancing quality of life for patients.

The subcutaneous infusion is indicated for pediatric patients aged 6 to 17 years who weigh less than 60 kg.

Enhanced dermatologic management reduces skin rash and improves quality of life for patients with EGFR-mutant non-small cell lung cancer.

Embedding a pharmacist in the dermatology clinic improved clinical and financial outcomes.

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

Patients should understand that routine skin care is an important facet in the overall management of diabetes.

Cynthia Ryan, PharmD, BCPS, discusses practical, evidence-based strategies for pharmacists to identify, prevent, and manage dermatologic toxicities associated with cancer therapies, emphasizing interdisciplinary collaboration, patient education, and proactive supportive care to improve adherence and outcomes.

The seasonal surge in skin irritations underscores the ongoing need for effective and convenient remedies.

New trial results reveal icotrokinra's effectiveness in achieving significant skin clearance for challenging scalp and genital psoriasis.

Intravenous immunoglobulin (IVIG) treatment for dermatologic conditions shows effectiveness but poses risks of kidney decline and thromboembolism, necessitating careful monitoring.

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.

Explore the intriguing connections between bulldogs and human medical conditions, revealing insights into congenital disorders and their treatments.

The designation was supported based on data from the randomized, double-blind, active-controlled phase 3 interchangeability study.

Matthew Zirwas, MD, addresses the significant financial burden associated with the medication, emphasizing the importance of pharmacists in navigating prior authorizations and access patient support programs.

Although the 16-week end point was not met, tezepelumab demonstrated meaningful effects in patients with chronic spontaneous urticaria (CSU) after 32 weeks.

Icotrokinra, an oral pill that blocks the IL-23 receptor, had a favorable safety profile in adults and adolescents 12 years and older with moderate-to-severe plaque psoriasis.

Efficacy and tolerability of topical treatments can vary by region, particularly sensitive areas such as the face and neck.

Embedding a pharmacist in the dermatology clinic improved clinical and financial outcomes.

Through frequent interactions, pharmacists can discuss patients' treatment satisfaction, adherence issues, or potential adverse events.

Rezpegaldesleukin is designed to balance the body’s immune system response through activation of regulatory T-cells.

These results provide a pediatric lens into the potential risk of thromboembolic events in patients with dermatomyositis.

Calcipotriol in combination with 5-FU triggers Th2 immunity to prevent skin cancer.

Treatment with IVIG leads to high responses 6 months following the initiation of therapy.

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.